BioNTech and Bristol Myers Squibb (BMS) have announced a strategic partnership valued at up to $11.1 billion to co-develop and co-commercialize BNT327, a bispecific antibody targeting PD-L1 and VEGF-A
The agreement includes a $1.5 billion upfront payment, $2 billion in non-contingent anniversary payments through 2028, and up to $7.6 billion in milestone-based payments from BMS.
NBNT327 is currently in Phase 3 trials for extensive-stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC), with plans to initiate a trial for triple-negative breast cancer (TNBC) by the end of 2025.
The collaboration reflects the growing industry focus on bispecific antibodies as a promising approach in oncology, combining immune activation with anti-angiogenic effects.
Strategic Partnership Overview
In a move poised to reshape the oncology landscape, German biotech firm BioNTech SE and U.S. pharmaceutical giant Bristol Myers Squibb (BMS) have entered into a global partnership to co-develop and co-commercialize BNT327, a next-generation bispecific antibody designed to target PD-L1 and VEGF-A.
The agreement, announced on June 2, 2025, entails a financial commitment of up to $11.1 billion from BMS, including an upfront payment of $1.5 billion, $2 billion in non-contingent anniversary payments through 2028, and up to $7.6 billion in milestone-based payments tied to development, regulatory, and commercial achievements.
BNT327: A Novel Therapeutic Approach
BNT327 represents a novel therapeutic approach in oncology, combining the mechanisms of immune checkpoint inhibition and angiogenesis blockade. By simultaneously targeting PD-L1 and VEGF-A, the antibody aims to enhance anti-tumor immune responses while disrupting the tumor’s blood supply.
This dual-action strategy is currently being evaluated in multiple clinical trials, including Phase 3 studies for extensive-stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC). A Phase 3 trial for triple-negative breast cancer (TNBC) is anticipated to commence by the end of 2025.
Terms of the Collaboration
Under the terms of the partnership, BioNTech and BMS will share global development and commercialization responsibilities, with profits and losses split equally. Both companies retain the right to independently develop BNT327 for additional indications and in combination with other therapies.
Industry Implications
Closing the European innovation gap isn’t just about investing in technology, but also about This collaboration underscores the increasing interest in bispecific antibodies within the pharmaceutical industry, as companies seek innovative treatments that can address multiple pathways involved in cancer progression. The BioNTech-BMS alliance positions both firms at the forefront of this emerging field, potentially offering new hope for patients with hard-to-treat cancers.
Leadership Perspectives
BioNTech’s CEO, Dr. Ugur Sahin, emphasized the strategic importance of the partnership, stating that it aims to accelerate the development of BNT327 and unlock its full potential across various tumor types.
For BMS, the deal represents a significant investment in expanding its oncology portfolio, particularly in the realm of immuno-oncology, as the company seeks to maintain its competitive edge in the face of patent expirations and evolving treatment paradigms.